Aberrant splicing is a hallmark of leukemias with mutations in splicing factor (SF)-encoding genes. Here we investigated its prevalence in pediatric B-cell acute lymphoblastic leukemias (B-ALL), where SFs are not mutated. By comparing them to normal pro-B cells, we found thousands of aberrant local splice variations (LSVs) per sample, with 279 LSVs in 241 genes present in every comparison. These genes were enriched in RNA processing pathways and encoded ~100 SFs, e.g. hnRNPA1. hnRNPA1 3’UTR was most pervasively misspliced, yielding the transcript subject to nonsense-mediated decay. Thus, we knocked it down in B-lymphoblastoid cells, identified 213 hnRNPA1-dependent splicing events, and defined the hnRNPA1 splicing signature in pediatric leukemias.
More...Aberrant splicing is a hallmark of leukemias with mutations in splicing factor (SF)-encoding genes. Here we investigated its prevalence in pediatric B-cell acute lymphoblastic leukemias (B-ALL), where SFs are not mutated. By comparing them to normal pro-B cells, we found thousands of aberrant local splice variations (LSVs) per sample, with 279 LSVs in 241 genes present in every comparison. These genes were enriched in RNA processing pathways and encoded ~100 SFs, e.g. hnRNPA1. hnRNPA1 3’UTR was most pervasively misspliced, yielding the transcript subject to nonsense-mediated decay. Thus, we knocked it down in B-lymphoblastoid cells, identified 213 hnRNPA1-dependent splicing events, and defined the hnRNPA1 splicing signature in pediatric leukemias. One of its elements was DICER1, a known tumor suppressor gene; its LSVs involved the 5’ UTR, suggestive of splicing as a mechanism of translational deregulation. Additionally, we searched for LSVs in other leukemia and lymphoma drivers and discovered 81 LSVs in 41 genes. 77 LSVs were confirmed using two large independent B-ALL RNA-seq datasets. In fact, the twenty most common B-ALL drivers showed higher prevalence of aberrant splicing than of somatic mutations. Thus, post-transcriptional deregulation of SF can drive widespread changes in B-ALL splicing and likely contribute to disease pathogenesis.
Overall design: Refer to individual Series
Less...| Accession | PRJNA475681; GEO: GSE115656 |
| Type | Umbrella project |
| Publications | Black KL et al., "Aberrant splicing in B-cell acute lymphoblastic leukemia.", Nucleic Acids Res, 2018 Nov 30;46(21):11357-11369 |
| Grants | - "Cassette exons in neoplastic pro-B-cells: implications for immunotherapy" (Grant ID U01 CA232563, National Cancer Institute)
|
| Submission | Registration date: 12-Jun-2018 Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania |
| Relevance | Superseries |
Project Data:
| Resource Name | Number of Links |
|---|
| Sequence data |
| SRA Experiments | 38 |
| Publications |
| PubMed | 1 |
| PMC | 1 |
| Other datasets |
| BioSample | 38 |
| GEO DataSets | 4 |
Alternative splicing analysis of pediatric B-cell acute lymphoblastic leukemia compared to normal bone marrow derived pro-B cells encompasses the following 3 sub-projects:
| Project Type | Number of Projects |
| Transcriptome or Gene expression | 3 |
BioProject accession | Organism | Title |
|---|
| PRJNA475682 | Homo sapiens | Aberrant splicing in B-cell acute lymphoblastic leukemia [cell line] (Children's Hospital of Philadelphia,...) | | PRJNA475683 | Homo sapiens | Aberrant splicing in B-cell acute lymphoblastic leukemia [B-ALL] (Children's Hospital of Philadelphia,...) | | PRJNA475684 | Homo sapiens | Bone marrow derived human B cells [normal proB] (Children's Hospital of Philadelphia,...) |
|